^
    4ms
    JAB-21822 3002: JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=392, Recruiting, Jacobio Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • glecirasib (JAB-21822) • JAB-3312
    5ms
    Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. (PubMed, J Med Chem)
    JAB-3312 was well-tolerated in animal models, and a close correlation was observed between the plasma concentration of JAB-3312 and the p-ERK inhibition in tumors. Currently, JAB-3312 is undergoing clinical trials as a potential anticancer agent.
    Journal
    |
    PD-1 (Programmed cell death 1)
    |
    JAB-3312
    8ms
    JAB-21822 3002: JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=392, Not yet recruiting, Jacobio Pharmaceuticals Co., Ltd.
    New P3 trial • Metastases
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • glecirasib (JAB-21822) • JAB-3312
    11ms
    Study to investigate JAB-3312 Combination Therapies in Adult Patients with Advanced Solid Tumors (clinicaltrialsregister.eu)
    P2, N=20, Ongoing, Jacobio Pharmaceuticals Co., Ltd.
    New P2 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Lumakras (sotorasib) • JAB-3312
    over1year
    Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors (ESMO 2023)
    Conclusions Glecirasib plus JAB-3312 was well tolerated with promising efficacy in KRAS p.G12C NSCLC. Currently, dose expansion is underway to further evaluate efficacy and safety.
    Clinical • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    glecirasib (JAB-21822) • JAB-3312
    over1year
    JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Jacobio Pharmaceuticals Co., Ltd. | Trial completion date: Jun 2023 --> Feb 2024 | Trial primary completion date: Mar 2023 --> Jan 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Tagrisso (osimertinib) • Lumakras (sotorasib) • Mektovi (binimetinib) • JAB-3312
    over2years
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation (clinicaltrials.gov)
    P1/2, N=124, Recruiting, Jacobio Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting | N=72 --> 124
    Enrollment open • Enrollment change • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    glecirasib (JAB-21822) • JAB-3312
    almost3years
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, Jacobio Pharmaceuticals Co., Ltd.
    New P1/2 trial • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    glecirasib (JAB-21822) • JAB-3312